Treatment of Symptomatic Chronic Adenotonsillar Hypertrophy With Amoxicillin/Clavulanate Potassium: Short- and Long-term Results
- 1 April 1998
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 101 (4) , 675-681
- https://doi.org/10.1542/peds.101.4.675
Abstract
Objective. To evaluate the short- and long-term effects of treatment of symptomatic chronic adenotonsillar hypertrophy (CATH) with a 30-day course of amoxicillin/clavulanate potassium (AMOX/CLAV).Patients. Children 2 to 16 years of age with obstructive symptoms attributable to CATH, who did not have a history of recurrent adenotonsillitis.Design. A prospective, randomized, double-blinded, placebo-controlled trial.Setting. Ambulatory clinic of a tertiary care hospital.Intervention. Patients were randomly treated with 30-day courses of either placebo (PLAC) or AMOX/CLAV (40 mg/kg in 3 divided doses daily).Outcome Measures. Patients' signs and symptoms were assessed by physical examination and by both physician and parental forced-choice questionnaires 1, 3, and 24 months after treatment. The decision to proceed to surgery or to continue expectant management was made for all patients by the same physician, based on reported symptoms and physical findings.Results. Treatment with a 30-day course of AMOX/CLAV significantly reduced the need for surgery in the short term compared with PLAC (37.5% vs 62.7%) at 1-month follow-up). The reduced need for surgery in the AMOX/CLAV-treated group persisted at 3 months (AMOX/CLAV 54.5% vs PLAC 85.7%) and 24 months (AMOX/CLAV 83.3% vs PLAC 98.0%).Conclusions. A 30-day course of AMOX/CLAV significantly reduces the need for surgery in children with obstructive adenotonsillar hypertrophy at 1-month follow-up. This relative reduction persists at 3 and 24 months posttreatment, although the absolute percentages of patients requiring surgery increased in both groups as time after treatment increased. The reduction in symptoms in AMOX/CLAV-treated patients is modest but significant even in long-term follow-up. The precise role of this treatment for CATH is yet to be determined; however, our results suggest that a 30-day course of AMOX/CLAV can be used in situations when a temporary relief in symptoms is desirable or surgery would incur unacceptable risk.Keywords
This publication has 19 references indexed in Scilit:
- Effect of specific bacteria on lymphocyte proliferation in diseased and nondiseased tonsilsThe Laryngoscope, 1993
- Bacteriology and Immunology of Normal and Diseased Adenoids in ChildrenJAMA Otolaryngology–Head & Neck Surgery, 1993
- The relationship of tonsil bacterial concentration to surface and core cultures in chronic tonsillar disease in childrenInternational Journal of Pediatric Otorhinolaryngology, 1991
- Amoxicillin/Clavulanate Treatment in Secretory Otitis Media: Bacteriological Findings in the NasopharynxActa Oto-Laryngologica, 1990
- Microbiology of Obstructive Tonsillar Hypertrophy and Recurrent TonsillitisJAMA Otolaryngology–Head & Neck Surgery, 1989
- The role of haemophilus influenzae in the pathogenesis of tonsillar hypertrophy in childrenThe Laryngoscope, 1988
- Microbiology of the Tonsils and Adenoids in a Pediatric PopulationJAMA Otolaryngology–Head & Neck Surgery, 1988
- The immunology of tonsils in children: The effect of bacterial load on the presence of b‐ and t‐cell subsetsThe Laryngoscope, 1988
- Postoperative complications following tonsillectomy and adenoidectomy—who is at risk?International Journal of Pediatric Otorhinolaryngology, 1987
- Ear, Nose, and Throat Operations in the United States, 1979 to 1984JAMA Otolaryngology–Head & Neck Surgery, 1986